Paysign Sees Unusually Large Options Volume (NASDAQ:PAYS)

Key Points

• Call-option activity surged: Investors traded 2,581 Paysign call options on Wednesday, about 712% above the typical daily volume of 318.
• Quarterly results beat estimates: Revenue hit a record $30.8 million, up 42.6% year over year, while EPS of $0.11 topped the $0.09 consensus. However, 2026 EPS guidance of $0.37–$0.38 fell short of the $0.51 consensus, and a customer pullback is weighing on the outlook.
• Paysign shares fell 3.6% to $9.77, and Maxim Group downgraded the stock from “buy” to “hold.”

Paysign, Inc. (NASDAQ:PAYS - Get Free Report) saw some unusual options trading on Wednesday. Stock investors acquired 2,581 call options on the company. This is an increase of approximately 712% compared to the typical daily volume of 318 call options.

Paysign News Summary

Investors following PAYS have been watching these news items:

• Positive Sentiment: Third-quarter revenue reached a record $30.8 million, up 42.6% year over year. EPS of $0.11 beat the $0.09 consensus, while operating margin more than tripled to 23.8%. Pharma revenue rose 109.8%. Paysign third-quarter results
• Negative Sentiment: FY 2026 EPS guidance of $0.37–$0.38 is below the $0.51 consensus, raising concerns about profitability relative to expectations. Paysign Q3 earnings call transcript
• Negative Sentiment: A customer’s pullback is weighing on expected future revenue, and Maxim Group downgraded PAYS from “buy” to “hold,” adding pressure to the outlook. Customer pullback and future revenue Maxim Group ratings

Insider Activity at Paysign

In other Paysign news, CEO Mark Newcomer sold 50,000 shares of Paysign stock in a transaction dated Friday, October 9th. The stock was sold at an average price of $15.34, for a total value of $767,000.00. Following the transaction, the chief executive officer owned 9,113,002 shares in the company, valued at $139,793,450.68. The trade was a 0.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Michael Ngo sold 79,925 shares of Paysign stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $12.74, for a total value of $1,018,244.50. Following the completion of the transaction, the insider owned 2,350,000 shares in the company, valued at $29,939,000. This trade represents a 3.29% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 259,904 shares of company stock valued at $3,402,424 over the last quarter. 24.50% of the stock is owned by corporate insiders.

Institutional Trading of Paysign

Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of Paysign in the second quarter worth about $25,219,000. Punch & Associates Investment Management Inc. acquired a new stake in Paysign during the 2nd quarter valued at approximately $16,983,000. Renaissance Technologies LLC lifted its stake in Paysign by 17.4% during the 1st quarter. Renaissance Technologies LLC now owns 1,531,072 shares of the company's stock valued at $9,033,000 after acquiring an additional 227,300 shares during the period. AWM Investment Company Inc. acquired a new stake in Paysign during the 2nd quarter valued at approximately $6,560,000. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Paysign by 16.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 575,619 shares of the company's stock valued at $3,396,000 after acquiring an additional 82,736 shares during the last quarter. Hedge funds and other institutional investors own 25.89% of the company's stock.

Paysign Stock Down 3.6%

Shares of Paysign stock traded down $0.37 during midday trading on Wednesday, hitting $9.77. The company had a trading volume of 490,435 shares, compared to its average volume of 752,638. The company has a fifty day simple moving average of $13.82 and a 200 day simple moving average of $8.63. The stock has a market cap of $551.63 million, a price-to-earnings ratio of 29.61 and a beta of 0.92. Paysign has a 12-month low of $3.08 and a 12-month high of $16.15.

Paysign (NASDAQ:PAYS - Get Free Report) last released its earnings results on Monday, November 9th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.02. Paysign had a net margin of 18.48% and a return on equity of 37.20%. The company had revenue of $30.80 million for the quarter, compared to the consensus estimate of $29.02 million. As a group, analysts expect that Paysign will post 0.58 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on PAYS shares. Maxim Group downgraded shares of Paysign from a "buy" rating to a "hold" rating in a research note on Wednesday. Lake Street Capital upped their price target on Paysign from $13.00 to $15.00 and gave the stock a "buy" rating in a research report on Tuesday, September 15th. Wall Street Zen lowered Paysign from a "strong-buy" rating to a "buy" rating in a report on Sunday, August 16th. DA Davidson raised their price objective on Paysign from $12.00 to $15.00 and gave the stock a "buy" rating in a research report on Wednesday, September 30th. Finally, Weiss Ratings raised Paysign from a "buy (b-)" rating to a "buy (b)" rating in a research report on Thursday, October 8th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $15.00.

About Paysign

Paysign, Inc. provides prepaid card programs, payment processing and related financial technology services. Its platform supports organizations that need to distribute funds and manage payments, including businesses in the healthcare sector. The company serves plasma collection centers with donor compensation and payment solutions, and works with pharmaceutical companies on patient assistance and affordability programs. Its services also support payments for clinical trials and other disbursement needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.